DE69613984D1 - Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung - Google Patents

Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung

Info

Publication number
DE69613984D1
DE69613984D1 DE69613984T DE69613984T DE69613984D1 DE 69613984 D1 DE69613984 D1 DE 69613984D1 DE 69613984 T DE69613984 T DE 69613984T DE 69613984 T DE69613984 T DE 69613984T DE 69613984 D1 DE69613984 D1 DE 69613984D1
Authority
DE
Germany
Prior art keywords
protein kinase
oligonucleotids
specific modified
oligonucleotides
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69613984T
Other languages
English (en)
Other versions
DE69613984T2 (de
Inventor
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of DE69613984D1 publication Critical patent/DE69613984D1/de
Publication of DE69613984T2 publication Critical patent/DE69613984T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69613984T 1995-09-22 1996-09-19 Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung Expired - Fee Related DE69613984T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/532,979 US5969117A (en) 1995-08-17 1995-09-22 Modified protein kinase a-specific oligonucleotide
PCT/US1996/015084 WO1997011171A1 (en) 1995-09-22 1996-09-19 Modified protein kinase a-specific oligonucleotides and methods of their use

Publications (2)

Publication Number Publication Date
DE69613984D1 true DE69613984D1 (de) 2001-08-23
DE69613984T2 DE69613984T2 (de) 2001-11-29

Family

ID=24123968

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69613984T Expired - Fee Related DE69613984T2 (de) 1995-09-22 1996-09-19 Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung

Country Status (8)

Country Link
US (1) US5969117A (de)
EP (1) EP0846170B1 (de)
JP (1) JPH11512601A (de)
AT (1) ATE203271T1 (de)
AU (1) AU7241296A (de)
CA (1) CA2232724A1 (de)
DE (1) DE69613984T2 (de)
WO (1) WO1997011171A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) * 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US7074768B2 (en) * 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US6624293B1 (en) * 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
AU6328598A (en) * 1997-03-12 1998-09-29 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
US7192932B1 (en) 1997-04-29 2007-03-20 Lauras As Use of immunomodulating agents
NO971997D0 (no) * 1997-04-29 1997-04-29 Kjetil Tasken Bruk av immunmodulerende midler
EP1080186A2 (de) * 1998-05-27 2001-03-07 Lauras AS Verfahren zur modifizierung der aktivität von proteinen der pka signaltransduktionskaskade
US20030105037A1 (en) * 2001-10-06 2003-06-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-gamma expression
WO2004053073A2 (en) * 2002-12-05 2004-06-24 The Research Foundation Of State University Of Newyork HIGH EFFICACY ANTISENSE Riα PKA POLY-DNP OLIGORIBONUCLEOTIDES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220007A (en) * 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5470967A (en) * 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
EP0632832A1 (de) * 1993-01-21 1995-01-11 The Salk Institute For Biological Studies Protein kinase
CA2159350A1 (en) * 1993-03-31 1994-10-13 Sudhir Agrawal Modified oligonucleotides having improved anti-influenza activity
JPH1135595A (ja) * 1994-12-02 1999-02-09 Pola Chem Ind Inc アンチセンスオリゴヌクレオチド及びそれを用いた制癌剤
AU5325696A (en) * 1995-04-03 1996-10-23 Hybridon, Inc. Method of modulating gene expression without depleting compl ement

Also Published As

Publication number Publication date
EP0846170B1 (de) 2001-07-18
EP0846170A1 (de) 1998-06-10
WO1997011171A1 (en) 1997-03-27
US5969117A (en) 1999-10-19
ATE203271T1 (de) 2001-08-15
DE69613984T2 (de) 2001-11-29
JPH11512601A (ja) 1999-11-02
AU7241296A (en) 1997-04-09
CA2232724A1 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
FI951612A0 (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
ATE343638T1 (de) Oligonukleotidliganden mit hoher affinität für pdgf
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
DE69627314D1 (de) Kettenabbruchgruppen, ihre verwendung zur sequenzierung und synthese von nukleinsäuren und verfahren zu ihrer herstellung
LTIP1531A (en) Method for the determination of dna molecule nucleotides bases sequence
DE69834699D1 (de) Neues protein und verfahren zu dessen herstellung
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
DE69628864D1 (de) Invertierte chimäre und hybrid-oligonukleotide
DE69634751D1 (de) MODIFIZIERTE METHIONINASE, DEREN VERWENDUNG, REKOMBINANTE WIRTsZELLEN DIE GROSSE MENGEN VON METHIONINASE PRODUZIEREN UND VERFAHREN ZUR AUFREINIGUNG VON METHIONINASE
DE69623005T2 (de) Verbesserte verfahren zur enzymatischen synthese von oligosacchariden
DE69808274T2 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
DE69613984T2 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
DE69831007D1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
EP0641215A4 (de) Protease-resistente analoge des thrombomodulin.
ATE296886T1 (de) Männliche fertilität vermittelnde nukleotidsequenzen und verfahren zu ihrer verwendung
DE69637941D1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
DE69803822D1 (de) Verbessertes Verfahren zur Hydrierung von Maleinsäure zu 1,4-Butandiol
DE69637516D1 (de) Verfahren für die Amplifizierung von Nukleinsäure-Sequenzen
AU6328598A (en) Modified protein kinase a-specific oligonucleotides and methods of their use
DE59611131D1 (de) Acarbose-Biosynthesegene aus Actinoplanes sp., Verfahren zu ihrer Isolierung sowie ihrer Verwendung
DE69800114D1 (de) Verfahren zur Hydrierung von Cyanopropanaldehyden enthaltend Cyanopropionaldehydacetalen
ATE55411T1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
ATE65543T1 (de) Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
MX9709747A (es) Serpina novedosa derivada de hipotalamo humano.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee